Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ceftazidime before ERCP to prevent post-ERCP pancreatitis
NL-OMON49650Completed
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
- Start
- Jan 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Ceftazidime with Placebo control (2 arms). Primary endpoints: Incidence of post-ERCP pancreatitis the day after ERCP and Delayed post-ERCP pancreatitis up to 4 weeks. Started Jan 2021; status: completed.
02
Drugs
ceftazidime
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NL-OMON49650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49650.